336 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
GSK GlaxoSmithKline PLC $41.27 $102.34B Uptrend
Article Searches
Is GlaxoSmithKline plc Stock a Buy? https://www.fool.com/investing/2018/05/31/is-glaxosmithkline-plc-stock-a-buy.aspx?source=iedfolrf0000001 May 31, 2018 - GlaxoSmithKline is in the midst of a turnaround under a new management team. Should investors "trust the process"?
LabCorp Extends Aetna Agreement, Expands Diagnostics Business http://www.zacks.com/stock/news/305787/labcorp-extends-aetna-agreement-expands-diagnostics-business?cid=CS-ZC-FT-305787 May 31, 2018 - The expanded agreement enables LabCorp (LH) to serve as a preferred national laboratory to almost all of Aetna's members starting Jan 1, 2019.
AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why http://www.zacks.com/stock/news/305601/astrazeneca-azn-stock-on-growth-path-this-year-heres-why?cid=CS-ZC-FT-305601 May 30, 2018 - AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline
Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan http://www.zacks.com/stock/news/305624/glaxo-innoviva-file-for-approval-of-trelegy-ellipta-in-japan?cid=CS-ZC-FT-305624 May 30, 2018 - Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.
As GSK broadens respiratory portfolio, Triangle at the center http://feeds.bizjournals.com/~r/industry_6/~3/9jQbsDaCNTg/as-gsk-broadens-respiratory-portfolio-triangle-at.html May 29, 2018 - As pharmaceuticals giant GlaxoSmithKline shifts and broadens its respiratory portfolio, the Triangle is at the center of the activity.
3 Dividend Stocks That Pay You Better Than ExxonMobil Does https://www.fool.com/investing/2018/05/25/3-dividend-stocks-that-pay-you-better-than-exxonmo.aspx?source=iedfolrf0000001 May 25, 2018 - Not only do these three stocks pay you more, but these investors think they have better prospects, too.
Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval http://www.zacks.com/stock/news/305045/dow-30-stock-roundup-ges-transportation-unit-to-merge-with-wabtec-jj-glaxos-hiv-drug-gets-eu-approval?cid=CS-ZC-FT-305045 May 25, 2018 - The Dow endured another volatile week marked by key geopolitical developments.
The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive http://www.zacks.com/stock/news/304563/the-zacks-analyst-blog-highlights-cisco-kraft-heinz-sinopec-glaxo-and-progressive?cid=CS-ZC-FT-304563 May 23, 2018 - The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive
Top Stock Reports for Cisco, Kraft Heinz & Sinopec http://www.zacks.com/research-daily/163653/top-stock-reports-for-cisco-kraft-heinz-sinopec?cid=CS-ZC-FT-163653 May 22, 2018 - Top Stock Reports for Cisco, Kraft Heinz & Sinopec
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval http://www.zacks.com/stock/news/304425/glaxo-and-jjs-two-drug-hiv-regimen-juluca-gets-eu-approval?cid=CS-ZC-FT-304425 May 22, 2018 - Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

Pages: 123456...34

Page 1>